C57BL/6JCya-Ifi30em1/Cya
Common Name
Ifi30-KO
Product ID
S-KO-16272
Backgroud
C57BL/6JCya
Strain ID
KOCMP-65972-Ifi30-B6J-VA
Status
When using this mouse strain in a publication, please cite “Ifi30-KO Mouse (Catalog S-KO-16272) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Ifi30-KO
Strain ID
KOCMP-65972-Ifi30-B6J-VA
Gene Name
Product ID
S-KO-16272
Gene Alias
GILT, IP30
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 8
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000222087
NCBI RefSeq
NM_023065
Target Region
Exon 2~7
Size of Effective Region
~2.5 kb
Overview of Gene Research
Ifi30, also known as gamma-interferon-inducible lysosomal thiol reductase, is a crucial enzyme. It mainly exists in immune cells and functions in reducing protein disulfide bonds in endocytosis-mediated protein degradation. It is involved in antigen presentation and immune regulation, playing a role in pathways such as peptide antigen binding, cytokine binding, and MHC class II presentation [1,2]. It also has significance in processes like angiogenesis [3].
In breast cancer, high Ifi30 expression is associated with poor prognosis, and its knockdown reduces PD-L1 expression and inhibits breast cancer cell proliferation, migration, and invasion [1]. In glioma, high Ifi30 expression indicates malignancy and poor outcomes, and is an independent prognostic marker. It is also related to immune cell infiltration and immunosuppressive phenotypes [2,4]. In zebrafish, Ifi30 knockdown impairs caudal vein plexus formation, suggesting its role in sprouting angiogenesis [3].
In conclusion, Ifi30 is essential for immune regulation, antigen presentation, and angiogenesis. Studies using knockdown models in different organisms like zebrafish and in vitro cell models in human cancers such as breast cancer and glioma have revealed its role in disease-related processes. These findings provide potential targets for treating breast cancer and glioma [1-4].
References:
1. Li, Lei, Fei, Yinjiao, Dong, Tianfu, Liang, Mingxing, Tang, Jinhai. 2024. IFI30 as a key regulator of PDL1 immunotherapy prognosis in breast cancer. In International immunopharmacology, 133, 112093. doi:10.1016/j.intimp.2024.112093. https://pubmed.ncbi.nlm.nih.gov/38669947/
2. Liu, Xiu, Song, Chunyan, Yang, Shoubo, Chen, Feng, Li, Wenbin. 2020. IFI30 expression is an independent unfavourable prognostic factor in glioma. In Journal of cellular and molecular medicine, 24, 12433-12443. doi:10.1111/jcmm.15758. https://pubmed.ncbi.nlm.nih.gov/32969157/
3. Wang, Xiaoning, Ge, Xiaojuan, Qin, Yinyin, Liu, Dong, Chen, Changsheng. 2022. Ifi30 Is Required for Sprouting Angiogenesis During Caudal Vein Plexus Formation in Zebrafish. In Frontiers in physiology, 13, 919579. doi:10.3389/fphys.2022.919579. https://pubmed.ncbi.nlm.nih.gov/35910561/
4. Jiang, Wei, Zheng, Feifei, Yao, Taotao, Zheng, Wenjie, Yao, Ninghua. . IFI30 as a prognostic biomarker and correlation with immune infiltrates in glioma. In Annals of translational medicine, 9, 1686. doi:10.21037/atm-21-5569. https://pubmed.ncbi.nlm.nih.gov/34988195/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.